Idenix Pharma downgraded to "above average"
10/30/09 - Caris & Company
NEW YORK, October 30 (newratings.com) - Analysts at Caris & Company downgrade Idenix Pharma (IDIX) from "buy" to "above average." The target price has been reduced from $16 to $5.
Share Recommend this article to a friend add IDIX to my stocks and get e-mail alerts on Idenix Pharmaceuticals